CTLA4 and lung cancer: Dermatologic toxicities are among the most common immune-related adverse events encountered in daily practice when treating lung cancer with an estimated incidence of 44% following CTLA-4 inhibition and 34% with PD-1/PD-L1 targeting treatment (23).